{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:18:51Z","timestamp":1792606731262,"version":"4.5.0"},"reference-count":26,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>Objective: To review the safety, efficacy, and tolerability of vonoprazan for the treatment of Helicobacter pylori infection in adults. Data Sources: A literature search was performed through PubMed using the following key terms: vonoprazan, Voquezna, TAK-438, potassium-competitive acid blocker, H pylori, and gastrointestinal. Study Selection and Data Extraction: Selected articles included those which described clinical studies of the pharmacology, pharmacokinetics, efficacy, safety, or tolerability of vonoprazan. Data Synthesis: Vonoprazan works by competing with potassium on the proton pump to inhibit gastric acid secretion. Phase 3 clinical trials have shown that vonoprazan is noninferior to proton pump inhibitors (PPIs) as a component of H pylori eradication regimens. Vonoprazan has also shown promise in duodenal ulcer-healing rates and in reducing symptoms of heartburn. Common adverse effects associated with vonoprazan include nasopharyngitis, diarrhea, constipation, flatulence, dyspepsia, headache, and abdominal pain. Conclusion: Clinical practice guidelines recommend PPIs as the antisecretory agent of choice in H pylori eradication regimens with histamine-2 receptor antagonists (H2RAs) as potential alternatives. However, the use of either class of medications may be limited by adverse effects, drug interactions, and tolerability. Potassium-competitive acid blockers (P-CABs), like vonoprazan, may be safe and effective alternative antisecretory agents for H pylori eradication regimens, as well as other gastrointestinal disorders.<\/jats:p>","DOI":"10.1177\/87551225231166531","type":"journal-article","created":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T07:28:50Z","timestamp":1682148530000},"page":"139-146","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":47,"title":["Vonoprazan: A New Potassium-Competitive Acid Blocker"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-2906","authenticated-orcid":false,"given":"Erin","family":"St. Onge","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Phillips","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,22]]},"reference":[{"key":"bibr1-87551225231166531","unstructured":"Centers for Disease Control and Prevention (CDC).\n                      Helicobacter pylori\n                      : fact sheet for health care providers. CDC. Accessed December 8,2022. https:\/\/stacks.cdc.gov\/view\/cdc\/40603."},{"key":"bibr2-87551225231166531","unstructured":"Centers for Disease Control and prevention (CDC). Chapter 4: travel-related infectious diseases. CDC. Accessed February 22,2023. https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2020\/travel-related-infectious-diseases\/helicobacter-pylori."},{"key":"bibr3-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.563."},{"key":"bibr4-87551225231166531","volume-title":"Package insert","author":"Voquezna","year":"2022"},{"key":"bibr5-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16295."},{"key":"bibr6-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)83580-3"},{"key":"bibr7-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.170274."},{"key":"bibr8-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1009."},{"key":"bibr9-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13121."},{"key":"bibr10-87551225231166531","unstructured":"Drug approval review for vonoprazan fumarate (in Japanese), the pharmaceuticals and medical devices agency of Japan. 2014. Accessed December 12, 2022. https:\/\/www.pmda.go.jp\/."},{"key":"bibr11-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.185314."},{"key":"bibr12-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.08.001."},{"key":"bibr13-87551225231166531","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001735."},{"key":"bibr14-87551225231166531","unstructured":"The interview form for vonoprazan fumarate (Takecab tablets 10 mg and 20 mg) ver.S, (in Japanese). Takeda Pharmaceutical. 2015. http:\/\/www.takeda.co.jp\/."},{"key":"bibr15-87551225231166531","unstructured":"Prescribing information of Takecab tablets 10 mg and 20 mg ver.2 (in Japanese). 2015. Accessed December 12, 2022. http:\/\/www.takeda.co.jp\/."},{"key":"bibr16-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15837."},{"key":"bibr17-87551225231166531","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000101."},{"key":"bibr18-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318365."},{"key":"bibr19-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.09.041."},{"key":"bibr20-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.05.055."},{"key":"bibr21-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15700."},{"key":"bibr22-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17070."},{"key":"bibr23-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0368-z."},{"key":"bibr24-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13637."},{"key":"bibr25-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0326-7."},{"key":"bibr26-87551225231166531","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0521-7."}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225231166531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225231166531","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225231166531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:31:37Z","timestamp":1777602697000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225231166531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,22]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1177\/87551225231166531"],"URL":"https:\/\/doi.org\/10.1177\/87551225231166531","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,22]]}}}